Sernova Corp.’s (OTCQB: SEOVF) (TSX.V: SVA) (FSE: PSH) Continuous Glucose Monitoring System Approved to be Utilized in Clinical Trial
Food & Drug Administration grants Sernova Corp. notice of approval to utilize its Continuous Glucose Monitoring System in support of clinical trial of its Cell Pouch Global treatment market for type 1 diabetes on pace to grow to $13.6 billion by 2023 Sernova is a clinical stage company focusing on treatment of type 1 diabetes, hemophilia and other chronic metabolic diseases Sernova Corp. (OTCQB: SEOVF) (TSX.V: SVA) (FSE: PSH) has been approved to add its Continuous Glucose Monitoring System in support of the impending clinical trial of its Cell Pouch™ for the treatment of type 1 diabetes. The system will…







